Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 1-Year High – What’s Next?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s stock price hit a new 52-week high on Thursday . The stock traded as high as $17.98 and last traded at $17.9010, with a volume of 241638 shares. The stock had previously closed at $17.20.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Barclays increased their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, UBS Group boosted their target price on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Amneal Pharmaceuticals Trading Down 1.1%

The business’s fifty day moving average price is $15.05 and its 200 day moving average price is $13.89. The firm has a market capitalization of $5.69 billion, a price-to-earnings ratio of 46.97 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. As a group, sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 17.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. grew its position in Amneal Pharmaceuticals by 75.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after buying an additional 1,611,698 shares during the last quarter. Westshore Wealth LLC acquired a new position in Amneal Pharmaceuticals in the 3rd quarter valued at $13,833,000. Morgan Stanley raised its position in Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after buying an additional 1,069,400 shares during the last quarter. Finally, Penn Capital Management Company LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth $12,655,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.